Navigation Links
Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
Date:4/30/2008

SAN CARLOS, Calif., April 30 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2008 on Wednesday, May 7, 2008, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call beginning at 5:00 p.m. Eastern Time (ET).

Investors can access the press release and a live audio-only Webcast of the conference call through a link that is posted on the Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Wednesday, May 21, 2008.

To access the conference call, follow these instructions:

Dial: (866) 713-8562 (U.S.); (617) 597-5310 (international)

Passcode: 50572577 (Howard Robin is the host)

An audio replay will also be available shortly following the call through Wednesday, May 21, 2008 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 73371402.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing a robust pipeline of its own high-value therapeutics that addresses unmet medical needs by leveraging and expanding its technology platforms to improve known molecules.


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, ... oncology and drug-delivery therapies, today announced that an ... and Drug Administration voted 11 to 0 that ... skin) injection was favorable for patients in the ... lymphoma and chronic lymphocytic leukemia. The FDA action ...
(Date:3/29/2017)... ... 2017 , ... Cancer diagnostics and pathology workflow solution provider ... Association of Community Cancer Centers (ACCC) 43rd Annual Meeting, CANCERSCAPE at ... stakeholders from leading national organizations to share insights on how value-based care, drug ...
(Date:3/29/2017)... and NEWARK, Del. , March ... privately-held regenerative medicine company, and W. L. Gore ... company, today announced a collaborative research agreement whereby the ... cell therapy delivery device technologies that provide protection from ... decade, ViaCyte has been developing innovative stem cell-derived cell ...
(Date:3/29/2017)... Research and Markets has announced the addition of ... report to their offering. ... The study scope includes key agricultural ... synthetic biology tools and genome editing tools); synthetic biology-enabled chemicals ... and products are analyzed to determine present and future market ...
Breaking Biology Technology:
(Date:3/22/2017)... YORK , March 21, 2017 ... Marketing Cloud used by retailers such as 1-800-Flowers ... its platform — Product Recommendations and Replenishment. Using Optimove,s ... give more personalized product and replenishment recommendations to ... but also on predictions of customer intent drawn ...
(Date:3/16/2017)... HANOVER, Germany , March 16, 2017 CeBIT 2017 - Against ... Continue Reading ... Used combined in one project, multi-biometric solutions ... ... Identification Systems) ...
(Date:3/7/2017)... 2017 Brandwatch , the leading social intelligence company, ... Trust to uncover insights to support its reporting, help direct ... The UK,s leading youth charity will be using Brandwatch Analytics social ... a better understanding of the topics and issues that are a ... ...
Breaking Biology News(10 mins):